



## A Study of C677T Polymorphism of Methylene tetrahydrofolate Reductase (*MTHFR*) Gene and Its Susceptibility in Coronary Artery Disease

Javeed Ahmad Tantray<sup>1,2</sup>, K. Pratap Reddy<sup>1</sup>, Shiva Kumar Yerra<sup>3</sup>  
and Kaiser Jamil<sup>2\*</sup>

<sup>1</sup>Department of Zoology, Osmania University Hyderabad, Telangana, India.

<sup>2</sup>Department of Genetics, Bhagwan Mahavir Medical Research Centre, 10-1-1, Mahavir Marg, AC Guards, Hyderabad-500004, India.

<sup>3</sup>Department of Cardiology, Mahavir Hospital and Research Centre, 10-1-1, Mahavir Marg, AC Guards, Hyderabad- 500 004, Andhra Pradesh, India.

### Authors' contributions

*This work was carried out in collaboration between all authors. Author JAT made the study design, genetic analysis, and interpretation of data and drafting the manuscript. Author KPR helped in the study design and interpretation. Author KJ made study design, analysis and drafting. Author SKY contributed to selection of patients, participated in the acquisition of patient consent, helping with the laboratory investigations. All authors participated in the discussions revised the manuscript and approved the final version.*

### Article Information

DOI: 10.9734/AJOB/2018/39936

#### Editor(s):

(1) Tulay Askin Celik, Department of Biology, University of Adnan Menderes, Turkey.  
(2) Xing Li, Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic College of Medicine, USA.

#### Reviewers:

(1) Oscar Campuzano Larrea, University of Girona, Spain.  
(2) Jonny Karunia Fajar, Syiah Kuala University, Indonesia.  
(3) Mohammad Saifur, Brawijaya University, Indonesia.

Complete Peer review History: <http://prh.sdiarticle3.com/review-history/24556>

Original Research Article

Received 6<sup>th</sup> February 2018  
Accepted 22<sup>nd</sup> April 2018  
Published 11<sup>th</sup> May 2018

### ABSTRACT

**Background:** MTHFR has been implicated in several diseases like breast cancer and leukemia, where the deficiency of ferric acid has been shown to increase the disease progression as it is a highly polymorphic gene. However there are very few reports of its role in coronary artery disease (CAD). Hence our aim was to genotype the CAD patients and healthy controls with a particular polymorphism at the C677T region of the gene.

\*Corresponding author: E-mail: [kj.bmmrc@gmail.com](mailto:kj.bmmrc@gmail.com);  
E-mail: [javeedh3@gmail.com](mailto:javeedh3@gmail.com), [javeedhzoology786@gmail.com](mailto:javeedhzoology786@gmail.com);

**Methods:** After determining the biochemical and clinical parameters, we tried to correlate these parameters with the *MTHFR* C667T genotypes which were done by PCR-RFLP.

**Results:** The presence of the *MTHFR* C677T was significantly associated with CAD compared to healthy controls. The percentage was greater with other common risk factors such as age, sex, diabetes mellitus, hypertension, smoking in CAD patients than in the normal subjects.

**Conclusion:** This study investigated the role of genetic polymorphism of methylenetetrahydrofolate reductase (*MTHFR*) as a potential genetic marker associated with coronary artery disease.

**Keywords:** Coronary artery disease; genotypes, methylenetetrahydrofolate reductase; single nucleotide polymorphism; gene frequency; demographs.

## 1. INTRODUCTION

Cardiovascular disease remains the major cause of morbidity and death in developed countries. Coronary artery disease (CAD) due to atherosclerosis is associated with increased mortality and morbidity. Various risk factors have been found to be associated with the development of CAD. The role of diabetes mellitus, smoking and hyperlipidaemia as risk factors for CAD is well established. The major classic risk factors like diabetes, hypertension, and non-modifiable risk factors such as age, sex, and family history cannot fully explain why some individuals are prone to coronary artery disease and others are not. Pathological and epidemiological studies suggest that only about one half to two-thirds of the variation in anatomic extent of atherosclerosis and risk for atherosclerotic vascular disease can be explained by the classic risk factors. Therefore, many emerging risk factors have been investigated.

Coronary artery disease has a complex etiology generated by combined effects of both, genetic and environmental factors [1]. The polymorphic genes, encoding products involved in atherosclerotic process, predispose individuals to a greater or lower extent to CAD. However, traditional risk factors, such as cigarette smoking, hypercholesterolemia, hypertension and overweight, interacting with the genetic risk factors (in cumulative or synergistic ways), may increase or not the risk of the disease. It is known that interactions between genetic and environmental factors are very important in subjects with a high-risk genetic profile [2]. Genetic factors have greater contribution to the development of CAD at younger age [3].

It has been predicted that cardiovascular diseases will increase rapidly in India, and this country will be the host to more than half the cases of heart disease in the world within the

next 15 years [4]. Global Burden of Disease Study estimated that India faces the greatest burden due to coronary artery disease (CAD) [5].

Genetic polymorphism of methylenetetrahydrofolate reductase (*MTHFR*) has been the subject of increasing attention as a potential genetic marker associated with atherosclerosis [6,7]. The human 5,10-*MTHFR* gene is located at the end of the short arm of chromosome 1 (1p36.3), and the total length of the gene cDNA (complementary DNA) is 2.2 kb. *MTHFR* plays a crucial role in the metabolism of folates and irreversibly converts 5, 10-methylenetetrahydrofolate to 5 methyltetrahydrofolate. 5-methyltetrahydrofolate is the predominant circulatory form of folates and donates a methyl group for remethylation of homocysteine to methionine. Consecutively, methionine is metabolized to yield S-adenosylmethionine (SAM), the main methyl donor for important methylation reactions that are required for DNA repair. Impaired *MTHFR* activity may lead to homocysteine accumulation in plasma, and this condition may contribute towards progressive atherosclerosis through several mechanisms, including arterial endothelial function impairment, oxidative stress induction and promotion of inflammation and thrombosis [8,9].

A common thermolabile mutation in the *MTHFR* gene, consisting of a cytosine (C) to thymidine (T) substitution at nucleotide position 677, leads to the exchange of a highly conserved alanine to valine (677C→T, alanine →valine), resulting in reduced activity of this enzyme, affecting folate distribution. The *MTHFR* 677 TT genotype led to elevated homocysteine levels and DNA hypomethylation in folate-depleted subjects. [10,11]. Low serum folate levels are known to cause several cancers [12,13] by influencing DNA methylation [14,15].

*MTHFR* is one of the metabolic pathways for CAD and is a key regulatory gene of the

remethylation pathway. The C677T polymorphism (rs1801133) in *MTHFR* has been implicated in vascular disease [16]. The T677 allele is distributed widely among populations showing a high heterogeneity [17]. Its frequency varies in different geographical regions and ethnic groups. A number of studies have reported the frequencies of C677T in European and American Caucasian populations.

The objective of this study was also to investigate whether there is any difference in allele prevalence in *MTHFR* C677T polymorphism between subjects with CAD and subjects without CAD, as evaluated by means of coronary catheterization.

## 2. MATERIALS AND METHODS

This study was approved by the Institutional Ethics Committee of Mahavir Hospital and research centre Hyderabad India. The cases (n=100) were consecutively selected from Cardiology Wards/CCU of Mahavir Hospital and all patients were angiography confirmed CAD patients. Details of type of cardiac problems along with angiography findings, blood pressure, history of smoking, hypertension, diabetes, etc. were also recorded. The levels of lipid parameters like total cholesterol (TC), high-density lipoprotein-cholesterol (HDL-C.) LDL-C. and triglycerol (TG) were measured.

### 2.1 DNA Extraction and *MTHFR* C677T Polymorphism

Blood samples were drawn from the cases and controls and collected in tubes containing EDTA. The DNA samples were extracted from whole

blood by a salting-out procedure [18]. The DNA samples were analyzed for the C677T missense mutation using a polymerase chain reaction with locus-specific primers, followed by subsequent analysis of a restriction fragment length polymorphism created by the mutation, as described below.

#### 2.1.1 PCR conditions for *MTHFR* 677

Initial- denaturation-94°C for 8 Min, Denaturation-94°C for 1 Min, Annealing-63°C for 1 Min, Extension -72°C for 1 Min, Final extension-72°C for 7Min4°C, Forever Repeated for 40 cycles (18). The primer sequences were 5'- TGAAGGAGAAGGTGTCTGCGGGA-3' and 5'- AGGACGGTGCGTGAGAGTG-3'.

For *MTHFR* 677, the PCR yielded a 198 bp product, which on digestion with *Hinf*I produced 175 and 23 bp fragments for TT condition (homozygous polymorphic) and a 198,175 and 23 bp fragments for CT condition (heterozygous polymorphic). An undigested product length of 198 bp was retained by the wild types.

The 677C→T substitution creates a *Hinf*I recognition sequence, which digests the initial polymerase chain recognition product of 198 base pairs (bp) into 175- and 23-bp fragments (Fig. 1). The presence of the mutation was determined by digestion of the initial polymerase chain reaction product with *Hinf*I at 37°C for 24 h. The digested DNAs were separated on 3% agarose gel in 1x Tris borate EDTA buffer, followed by staining with ethidium bromide solution and the *MTHFR* C677T genotypes were typed by visualization under ultraviolet light.




Fig. 1. *MTHFR* PCR products after restriction digestion with *Hinf*I on 3% agarose gel  
Lane 1 = 100bp DNA Ladder, Lane 2,3,5 = CC genotypes, Lane 4 = CT genotypes

## 2.2 Statistical Analyses

The data are presented as Mean±SD. Statistical analyses, using SPSS version 10.0, included the  $\chi^2$  test for genotype and allele frequency comparison. Odds ratios and 95% confidence intervals were calculated as a measure of the relationships between CAD and *MTHFR* genotypes. The clinical characteristics were compared by the Student's *t*-test and C677T allele frequencies were estimated by gene counting methods. A *p*-value of less than 0.05 was regarded as being statistically significant.

## 3. RESULTS

### 3.1 Demographic Results

The mean age of cases (56males, 44 females) was 56.4± 2.6. The maximum number of cases n=45 (45 %) was seen in age group 50-60 yr. Of the 100 cases 60(60%) were smokers, 40 (40%) non smokers, 25(25 %) were alcoholics, and a majority of 75 (75 %) were non-vegetarians. The majority in the study group were found not to consume fruits and salads. 30 (30%) hypertension, 25 (25%) diabetes mellitus and 25 (25%) had family history of diabetes mellitus (Table 1). Majority of the cases (50, 50 %) had single vessel disease, 30 (30%) had double vessel and 20 (20 %) had triple vessel disease.

The mean age of controls (60 males, 50 females) was 55.4± 2.8. Among the 110 controls, 38 (34.54%) were smokers, 72 (65.45%) were non smokers, 25 (22.72%) hypertension, 11 (10%) diabetes mellitus, 15 (13.63) family history of diabetes mellitus (Table 1).

### 3.2 Clinical Parameters

General characteristics and levels of biochemical parameters like TC, HDL-, LDL-cholesterol, VLDL and TG of the study groups are shown in Table 2. Cases had significantly higher levels of TC and LDL cholesterol compared to control group.

The mean ± SD of Cholesterol was found to be 200 ± 47.1 in the patients and 148 ± 34.7 in the controls, the LDL was found to be 125 ± 39 in the patients and 111 ± 33 in the controls, HDL was 40.11 ± 14.12 in the patients and 42.50 ± 15.42 in the controls, and VLDL was 26.52 ± 13 in patients and 22.97 ± 11.21 in normal controls of our study. Triglycerides were found to be 153.18 ± 68.02 in the patients and 140.25 ± 68.15 in the controls. The difference was significant for cholesterol and LDL when cases of CAD were compared with controls.

**Table 1. Demographic details involved in this study**

	Subjects with CAD (n=100)	Subjects without CAD (n=110)	p-value
Age (mean±SD)	56.4±2.6	55.4± 2.8	0.008
Males	56 (56%)	60 (54.54%)	0.83
Females	44 (44%)	50 (45.45%)	0.83
Smoking	60 (60%)	38 (34.54%)	0.004
Hypertension	30 (30%)	25 (22.72%)	0.23
Diabetes mellitus	25 (25%)	11 (10%)	0.006
Family history	25 (25%)	15 (13.63%)	0.04

**Table 2. Shows the mean levels of lipid profile in the cases of CAD and controls**

	Subjects with CAD (n=100)	Subjects without CAD (n=110)	p-value
Mean total cholesterol (mg/dl)	200 ± 47.1	148 ± 34.7	< 0.001
Mean LDL cholesterol (mg/dl)	125 ± 39	111 ± 33	< 0.005
Mean HDL cholesterol (mg/dl)	40.11 ± 14.12	42.50 ± 15.42	0.24
Mean VLDL cholesterol (mg/dl)	26.52 ± 13.22	22.97 ± 11.21	0.03
Mean TG	153.18 ± 68.02	140.25 ± 62.15	0.15

### 3.3 Genotype Results

DNA extracted from blood samples was checked for quality and quantity on 1% agarose gel. After checking for the purity of DNA, PCR was carried out in 20 µl reactions. PCR for the *MTHFR* gene gave a 198-bp fragment following enzymatic digestion of the PCR product using *Hinf* I restriction enzyme and incubated at 37°C for 24 h. Then it was electrophoresed in a 2% agarose gel at 90V for 30mins, and visualized in gel documentation. Three results were obtained for *MTHFR* 677, the PCR yielded a 198 bp product, which on digestion with *Hinf* I produced a 175 and 23 bp fragments for TT condition (homozygous polymorphic) and a 198,175 and 23 bp fragments for CT condition (heterozygous polymorphic) (Fig. 1). An undigested product length of 198 bp was retained by the wild types.

A total of 100 cases were genotyped, in *MTHFR* 677, CC genotype was found in 69 (69%), CT genotype was found in 24 (24%) and TT genotype was found in 7 (7%). In controls CC genotype was found in 95 (86%), CT was found in 15 (14%) and TT was not found in controls in this study (Table 3). The genotype distribution in cases showed deviation from HWE ( $X^2 = 4.852$ , P value = 0.028) while the controls were in HWE ( $X^2 = 0.589$ , P value = 0.443).

### 3.4 Correlation between *MTHFR* C677T and Exogenous Factors

*MTHFR* genotypes (CC, CT and TT) were correlated with demographic factors like gender, smoking and lipid profile to investigate the effect of genetic polymorphism in modulating the risk of developing CAD. When *MTHFR* genotypes were correlated with gender, it was noted that there was no significant difference between males [CC, CT, and TT genotypes were in 69.65% (39 patients), 21.42% (12 patients), and 8.93% (5 patients)] and females [CC, CT, and TT genotypes were in 68.18% (30 patients), 27.28% (12 patients), and 4.54% (2 patients), respectively]. We also investigated the association between *MTHFR* genotypes versus smoking. In patients we observed that smokers with CAD were 66.66 % (40 patients) and 23.33 % (14 patients) with CC and CT genotypes than nonsmokers [29 patients (72.5%) 10 patients (25 %)] While as TT genotype shows higher frequency [6 patients (10%)] in smokers and 1 patient (2.5%) was found with same genotype in non smoker (Table 4).

The lipid profile (Total cholesterol, HDL-C and LDL-C, VLDL-C and Triglycerides) along with different genotype frequencies of *MTHFR* (C677T) polymorphism were calculated for CAD patients and have been expressed as mean ± standard deviations (Fig. 2).




Fig. 2. Showing the lipid profile (TC, HDL-C, LDL-C, VLDL-C and TG) along with genotype frequencies of *MTHFR* gene (C677T) polymorphism in CAD patients

**Table 3. MTHFR C677T genotype distributions in CAD Patients and controls**

Poymorphism	Genotype / Alleles	CAD n 100 (%)	Control n 110 (%)	Odds Ratio	95% CI	P-value
C677T	CC	69 (69%)	95 (86%)	0.35	0.17-0.70	0.003
	CT	24 (24%)	15 (14%)	2.0	0.98-4.07	0.05
	TT	7 (7%)	0 (0%)	17.7	0.99-3.14	0.05
	C	162	205	0.31	0.16 - 0.58	0.0003
	T	38	15	3.2	1.70 - 6.03	0.0003

**Table 4. Association between MTHFR C677T with exogenous risk factors**

MTHFR genotype	Males (n=56)	Females (n= 44)	Statistics
CC (69)	39	30	OR 1.07, 95% CI 0.45-2.5, P 0.87
CT (24)	12	12	OR 0.72, 95% CI 0.28-1.82, P 0.49
TT (7)	5	2	OR 2.0, 95% CI 0.37-11.15, P 0.40
MTHFR genotype	Smokers (n=60)	Non smokers (n= 40)	Statistics
CC (69)	40	29	OR 0.75, 95% CI 0.31-1.82,P 0.53
CT (24)	14	10	OR 0.91, 95% CI 0.35-2.32,P 0.84
TT (7)	6	1	OR 4.33, 95% CI 0.50-37.45,P 0.18

#### 4. DISCUSSION

Coronary artery disease (CAD) due to atherosclerosis is associated with increased mortality and morbidity. Various risk factors have been found to be associated with the development of CAD. A person's genetic makeup, reflected by his or her family history, may influence the risk of various forms of cardiovascular disease. *MTHFR* (*C677T*) gene is found to be polymorphic in both cases and controls. In present study we found CC (OR: 0.35, 95% CI; 0.17-0.70, p: 0.003), CT (OR: 2.0, 95% CI; 0.98-4.07, p: 0.05) and TT (OR: 17.7, 95% CI; 0.99-3.14, p: 0.05) genotypes were associated with CAD cases compared to controls and T and C alleles were highly significant (P: 0.0003) among cases as compared to controls. The significant deviation from HWE observed in the cases in our study could be due to several factors such as disparity in survival of carriers of the marker, genetic drift.

The primary objectives of this study was to assess the frequency distribution of the *MTHFR* *C677T* mutation in a large population of patients with angiographically documented severe CAD, in comparison to subjects with absence of CAD. An attempt was made to clarify the relative contribution of this genetic factor to lipid level, with particular reference to the interaction with an environmental factor potentially modifiable. There was a significant association between *C677T* polymorphism and CAD (OR: 2.0, 95%

CI; 0.98-4.07, p: 0.05) (Table 3). The present study comprised of maximum number of cases in age group of 50 to 60 years, and all the cases above the age of 45 years. The *C677T* polymorphism may predict CAD risk only in certain ethnic groups [19] and the significant association of polymorphisms in the *MTHFR* gene has been observed in this group.

The mean  $\pm$  SD of Cholesterol was found to be  $200 \pm 47.1$  in the patients and  $148 \pm 34.7$  in the controls, the LDL was found to be  $125 \pm 39$  in the patients and  $111 \pm 33$  in the control, HDL was  $40.11 \pm 14.12$  in the patients and  $42.50 \pm 15.42$  in the controls, and VLDL was  $26.52 \pm 13$  in patients and  $22.97 \pm 11.21$  in normal controls of our study, triglycerides were found to be  $153.18 \pm 68.02$  in the patients and  $140.25 \pm 68.15$  in the controls. Cases had significantly higher levels of TC and LDL cholesterol compared to control group. The difference was significant ( $P < 0.001$ ) for cholesterol, and LDL ( $p < 0.001$ ), when cases of CAD were compared with controls.

The *MTHFR* *C677T* polymorphism has been investigated for its association with several complex diseases in several studies across different populations; however, results are not consistent. One of the possible reasons for this could be attributed to variation in allelic frequency distribution in different population groups. The *C677T* allele frequency was found to be highest in European populations ranging from 24.1% to 64.3% and, hence, it is presumed to be

originated in Europe in the late state of human evolution. However, zero frequency of this allele is reported from African population [20]. In Indian population, distribution of 677T allele ranges from complete absence to 23.7% and highest frequency was reported from North-Indian population. Moreover, frequency of T allele is found to be relatively higher among caste populations as compared to that of tribal populations of India. Linguistically, Indo-European speakers have relatively higher T allele frequency followed by Tibeto-Burman, Dravidian, and Austro-Asiatic speakers [21].

Whereas it is now becoming clear that, at least in most of the populations studied so far, the C677T mutation cannot be considered as a single genetic risk factor for CAD. The genotype and phenotype characteristics study in our population confirms that the *MTHFR* polymorphism is a major determinant of coronary artery disease, but also clearly shows that it is not important as a single factor.

## 5. CONCLUSION

In conclusion, we have observed that the presence of the *MTHFR* C677T was significantly associated with CAD. The percentage was greater with other common risk factors such as age, sex, diabetes mellitus, hypertension, smoking in CAD patients than in the normal subjects. In addition, the levels of TC, LDL-C were more in CAD patients than controls as compared to HDL-C and VLDL.

## 6. STUDY LIMITATIONS

This study covered a relatively small number of patients in a single center study, so that future studies of larger patient populations are necessary to assess this finding.

## 7. FUNDING

The authors (JA and KPR) acknowledge the partial funding to carry out this work from UGC/NON-Net Fellowship (JA) and UGC-F-26/SAI (SAP) (KPR) at Osmania University.

## CONSENT

As per international standard or university standard, written patient's consent has been collected and preserved by the authors.

## COMPETING INTERESTS

Authors have declared that no competing interests exist.

## REFERENCES

1. Ross R. Atherosclerosis-an inflammatory disease. *N Engl J Med.* 1999;340:115–126.
2. Talmud PJ. How to identify gene-environment interactions in a multifactorial disease: CHD as an example. *Proc Nutr Soc.* 2004;63:5–10.
3. Chaer RA, Billeh R, Massad MG. Genetics and gene manipulation therapy of premature coronary artery disease. *Cardiology.* 2004;101:122–130.
4. Gupta R, Joshi P, Mohan V, Reddy KS, Yusuf S. Epidemiology and causation of coronary heart disease and stroke in India. *Heart.* 2008;94:16-26.
5. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global burden of disease study. *Lancet.* 1997;349:1498-504.
6. Arruda VR, von Zuben PM, Chiaparini LC, Annichino-Bizzacchi JM, Costa FF. The mutation Ala677-->Val in the methylene tetrahydrofolate reductase gene: A risk factor for arterial disease and venous thrombosis. *Thromb Haemost.* 1997;77(5): 818-21.
7. Tripathi R, Tewari S, Singh PK, Agarwal S. Association of homocysteine and methylene tetrahydrofolate reductase (*MTHFR* C677T) gene polymorphism with coronary artery disease (CAD) in the population of North India. *Genet Mol Biol.* 2010;33(2):224-8.
8. Castro R, Rivera I, Blom HJ, Jakobs C, Tavares de Almeida I. Homocysteine metabolism, hyperhomocystenemia and vascular disease: An overview. *J Inherit Metab Dis.* 2006;29(1):3-20.
9. Wald DS, Law M, Morris JK. The dose-response relation between serum homocysteine and cardiovascular disease: Implications for treatment and screening. *Eur J Cardiovasc Prev Rehabil.* 2004; 11(3):250-3.
10. Friso S, Choi SW, Girelli D, Mason JB, Dolnikowski GG, Bagley PJ, Olivieri O, Jacques PF, Rosenberg IH, Corrocher R and Selhub J. A common mutation in the 5,10-methylene tetrahydrofolate reductase

- gene affects genomic DNA methylation through an interaction with folate status. Proc Natl Acad Sci. 2002;99:5606-5611.
11. Ueland PM, Hustad S, Schneede J, Refsum H and Vollset ES: Biological and clinical implications of the MTHFR C677T polymorphism. Trends Pharmacol Sci. 2001;22:195-201.
  12. Weinstein SJ, Ziegler RG, Selhub J, Fears TR, Strickler HD, Brinton LA, Hamman RF, Levine RS, Mallin K, Stolley PD. Elevated serum homocysteine levels and increased risk of invasive cervical cancer in US women. Cancer Causes Control. 2001;12: 317-324.
  13. La Vecchia C, Negri E, Pelucchi C, Franceschi S. Dietary folate and colorectal cancer. Int J Cancer. 2002;102: 545-547.
  14. Sull JW, Jee SH, Yi S, Lee JE, Park JS, Kim S, Ohrr H. The effect of methylenetetrahydrofolate reductase polymorphism C677T on cervical cancer in Korean women. Gynecol Oncol. 2004;95: 557-563.
  15. Eto I, Krumdieck CL. Role of vitamin B12 and folate deficiencies in carcinogenesis. Adv Exp Med Biol. 1986;206:313-330.
  16. Masud R, Qureshi IZ. Tetra primer ARMS-PCR relates folate/homocysteine pathway genes and ACE gene polymorphism with coronary artery disease. Mol. Cell. Biochem. 2011;355:289–297.
  17. Pepe G, Camacho VO, Giusti B, Brunelli T, Marcucci R, et al. Heterogeneity in World Distribution of the Thermolabile C677T Mutation in 5,10-Methylenetetrahydrofolate reductase Am J Hum Genet. 1998;63: 917–920.
  18. Tantray JA, Reddy KP, Jamil K, Kumar YS. Pharmacodynamic and cytogenetic evaluation in CYP2C19\*2 and CYP2C19\*3 allelomorphism in South Indian population with clopidogrel therapy. Int J Cardiol. 2017;229:113-118. Epub 2016 Nov 11.
  19. Saffroy R, Pham P, Chiappini F, et al. The MTHFR 677C>T polymorphism is associated with an increased risk of hepatocellular carcinoma in patients with alcoholic cirrhosis. Carcinogenesis. 2004; 25(8):1443–1448.
  20. Saraswathy KN, Asghar M, Samtani R, et al. Spectrum of MTHFR gene SNPs C677T and A1298C: A study among 23 population groups of India. Molecular Biology Reports. 2012;39(4):5025–5031.
  21. Zafarmand MH, van der Schouw YT, Grobbee DE, de Leeuw PW, Bots ML. The M235T polymorphism in the AGT gene and CHD risk: Evidence of a Hardy-Weinberg equilibrium violation and publication bias in a meta-analysis. PLoS One. 2008;3(6): e2533.

© 2018 Tantray et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

*Peer-review history:*

*The peer review history for this paper can be accessed here:  
<http://prh.sdiarticle3.com/review-history/24556>*